Webinar

Complimentary webinar to learn how Altasciences can tackle your most challenging bioanalytical assays by combining the high sensitivity of the SCIEX 6500+ TripleQuad with ion mobility technology to achieve next level detection limits with unprecedented selectivity.

The objective of quantitative bioanalysis is to provide precise and accurate sample analysis results within the acceptable tolerance (variability), in line with the study scope, so that sponsors can make appropriate go/no-go decisions. For proactive and efficient study progression, stakeholders must fully understand the operational, logistical, technical, and scientific considerations for the bioanalytical phase of various study types within a drug development program. Webinar participants will receive insight on this framework and the relevant critical control points.

CNS drug development continues to evolve with changing regulations, particularly in light of prescription drug abuse and risk/benefit optimization.  The uncertainty with regulations around emerging therapeutics, including cannabinoids, adds to the confusion. Navigating a successful regulatory and commercial pathway for CNS drugs can pose challenges and delays when requirements are not met. In addition to NDA-enabling phase I studies, specialty studies may be required to further evaluate your risk/benefit profile and support a drug scheduling recommendation.